Teva gets US FDA nod for generic version of GSK's antiviral Valtrex
Teva Pharmaceutical Industries Ltd announced US Food and Drug Administration (FDA) approval and commercial launch of its generic version of GlaxoSmithKline's antiviral product, Valtrex (valacyclovir hydrochloride) Tablets 500 mg and 1 g.
Total annual sales of the product, including brand and generic sales, were approximately US$ 2.1 billion in the United States, based on IMS sales data.
Teva Pharmaceutical Industries, headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company.